Clinical Trial Update: GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

The GALLEX 4 long-term extension study evaluating Tesaglitazar in patients with Type 2 diabetes has been terminated (Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tesaglitazar (tesaglitazar)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: TERMINATED